Mallinson Joanne E, Constantin-Teodosiu Dumitru, Sidaway James, Westwood F Russell, Greenhaff Paul L
Centre for Integrated Systems Biology and Medicine, School of Biomedical Sciences, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK.
J Physiol. 2009 Jan 15;587(1):219-30. doi: 10.1113/jphysiol.2008.164699. Epub 2008 Nov 10.
Statins are used clinically for cholesterol reduction, but statin therapy is associated with myopathic changes through a poorly defined mechanism. We used an in vivo model of statin myopathy to determine whether statins up-regulate genes associated with proteasomal- and lysosomal-mediated proteolysis and whether PDK gene expression is simultaneously up-regulated leading to the impairment of muscle carbohydrate oxidation. Animals were dosed daily with 80 mg kg(-1) day(-1) simvastatin for 4 (n = 6) and 12 days (n = 5), 88 mg kg(-1) day(-1) simvastatin for 12 days (n = 4), or vehicle (0.5% w/v hydroxypropyl-methylcellulose and 0.1% w/v polysorbate 80; Control, n = 6) for 12 days by oral gavage. We found, in biceps femoris muscle, decreased Akt(Ser473), FOXO1(Ser253) and FOXO3a(Ser253) phosphorylation in the cytosol (P < 0.05, P < 0.05, P < 0.001, respectively) and decreased phosphorylation of FOXO1 in the nucleus after 12 days simvastatin when compared to Control (P < 0.05). This was paralleled by a marked increase in the transcription of downstream targets of FOXO, i.e. MAFbx (P < 0.001), MuRF-1 (P < 0.001), cathepsin-L (P < 0.05), PDK2 (P < 0.05) and PDK4 (P < 0.05). These changes were accompanied by increased PPARalpha (P < 0.05), TNFalpha (P < 0.01), IL6 (P < 0.01), Mt1A (P < 0.01) mRNA and increased muscle glycogen (P < 0.05) compared to Control. RhoA activity decreased after 4 days simvastatin (P < 0.05); however, activity was no different from Control after 12 days. Simvastatin down-regulated PI3k/Akt signalling, independently of RhoA, and up-regulated FOXO transcription factors and downstream gene targets known to be implicated in proteasomal- and lysosomal-mediated muscle proteolysis, carbohydrate oxidation, oxidative stress and inflammation in an in vivo model of statin-induced myopathy. These changes occurred in the main before evidence of extensive myopathy or a decline in the muscle protein to DNA ratio.
他汀类药物在临床上用于降低胆固醇,但他汀类药物治疗会通过一种尚不明确的机制引发肌病性改变。我们使用了他汀类药物性肌病的体内模型,以确定他汀类药物是否会上调与蛋白酶体和溶酶体介导的蛋白水解相关的基因,以及PDK基因表达是否会同时上调,从而导致肌肉碳水化合物氧化受损。动物每天经口灌胃给予80 mg kg⁻¹ day⁻¹辛伐他汀,持续4天(n = 6)和12天(n = 5),或给予88 mg kg⁻¹ day⁻¹辛伐他汀,持续12天(n = 4),或给予赋形剂(0.5% w/v羟丙基甲基纤维素和0.1% w/v聚山梨酯80;对照组,n = 6),持续12天。我们发现,与对照组相比,在服用辛伐他汀12天后,股二头肌胞质中Akt(Ser473)、FOXO1(Ser253)和FOXO3a(Ser253)的磷酸化水平降低(分别为P < 0.05、P < 0.05、P < 0.001),细胞核中FOXO1的磷酸化水平降低(P < 0.05)。与此同时,FOXO下游靶点即MAFbx(P < 0.001)、MuRF - 1(P < 0.001)、组织蛋白酶 - L(P < 0.05)、PDK2(P < 0.05)和PDK4(P < 0.05)的转录显著增加。与对照组相比,这些变化伴随着PPARα(P < 0.05)、TNFα(P < 0.01)、IL6(P < 0.01)、Mt1A(P < 0.01)mRNA增加以及肌肉糖原增加(P < 0.05)。服用辛伐他汀4天后RhoA活性降低(P < 0.05);然而,12天后其活性与对照组无差异。在他汀类药物诱导的肌病体内模型中,辛伐他汀下调PI3k/Akt信号通路,独立于RhoA,并上调FOXO转录因子及其下游基因靶点,这些靶点已知与蛋白酶体和溶酶体介导的肌肉蛋白水解、碳水化合物氧化、氧化应激和炎症有关。这些变化主要发生在出现广泛肌病证据或肌肉蛋白与DNA比值下降之前。